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Neonatal Abstinence Syndrome from Selective Serotonin
Reuptake Inhibitor Use During Pregnancy
Elizabeth Kramer, Maria Patnella, Rachel Bulko, Allie Harrison, Hannah Lamb, Manoranjan D'Souza M.D., Ph.D., assistant
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Abstract
Neonatal abstinence syndrome (NAS) is a concern for infants
born to mothers receiving treatment with a selective serotonin reuptake inhibitor (SSRI) throughout the pregnancy. The
risk of NAS associated with SSRI use during pregnancy varies
with the specific SSRI that is used by the patient during pregnancy. Common symptoms of NAS include premature delivery, gastrointestinal disturbances, irritability, low birth
weight, short length and lack of response to various stimuli.
Neonates that present with these symptoms can be scored
using either the Finnegan or Lipsitz scoring tools. Neonates
experiencing NAS can be calmed or treated using nonpharmacologic methods such as swaddling, rocking, exposure to
calming scents, soft light and soothing music. Drugs such as
morphine or phenobarbital may be used as needed. Monitoring children born with NAS is important as it is possible that
these children may express long-term behavioral, social and
intellectual developmental problems. While there are many
health care professionals involved in the care of NAS, pharmacists can play a large role in both preventing and treating
NAS. Importantly, pharmacists can work with pregnant
mothers to help prevent NAS by recommending SSRls that
have less risk of causing high serotonin levels in neonates.
Pharmacists can also help by offering nonpharmacologic
treatment options, when appropriate, or by developing protocols for the treatment of NAS.

have shown harm to a human fetus, but the drug can be used
if the benefits are considerably greater than the risk. Some
reports suggest that continuation of SSRI use during pregnancy affects the growth of the infant before and after birth.
Furthermore, if a woman continues to use SSRls in pregnancy there has been a link to neonatal abstinence syndrome
(NAS) and other birth abnormalities.z However, discontinuation of therapy is likely to worsen symptoms of depression in
the mother during pregnancy. 4 Therefore, carefully managing
depression during pregnancy is warranted to avoid adverse
outcomes for both the developing fetus and the mother.
Prevalence
It is estimated about 30 percent of newborns experience NAS
after maternaI-SSRI use.s Infants were more likely to
experience NAS with SSRI use during the third trimester.6
Particularly, paroxetine and fluoxetine have caused the most
reported cases of NAS.7 Sertraline and citalopram have also
resulted in NAS.I
Symptoms
The signs and symptoms most commonly associated with
NAS include premature delivery, low birth weight and short
length of neonates at the time of birth. Symptoms of NAS may
also include gastrointestinal (GI) disturbances, restlessness,
irritability, tremors and respiratory distress.a Seizures,
which are generally associated with opiate withdrawal, have
also been reported in severe cases of NAS.
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Introduction
Depression is a major concern for the overall population,
including pregnant women, with about 7 to 19 percent of
women experiencing depression at some point during their
pregnancies.I Depression is associated with low levels of serotonin, and selective serotonin reuptake inhibitors (SSRls),
which increase levels of serotonin in the brain, form the
mainstay of treatment in all patients suffering from
depression, including pregnant women. 2 Most SSRis have a
pregnancy Category C classification which means that no
controlled studies have been conducted in pregnant women,
but adverse effects have been found in studies with animals,
or no studies are given with either animals or women.3 It is
concluded that Category C medications can be given to the
patient if the evaluated benefits of the medication outweigh
the risks. Among the SSRls, paroxetine is an exception as it
has a Category D classification which means that studies
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Infants whose mothers took SSRis during the third trimester
of pregnancy may exhibit reactional delays when exposed to
positive and negative stimuli. Oberlander et al. reported a
decreased rate of facial reactions to pain in infants exposed
to SSRis in utero. 9 The study further reported delayed responses including kicks, toe-curling and swatting away irritants as a result of SSRI exposure in utero. However, it must
be known that motor skills in infants are not entirely coordinated at this stage of development.
In a study conducted by Sie et al., neonates reportedly expressed symptoms of NAS within 48 hours of birth.IO Infants
exposed to SSRis in utero did not cry as loudly compared to
infants who were never exposed to SSR!s in utero (control
group). These unresponsive infants, who either cried sparingly or not at ciJl, showed higher deviation from the control
group symptomatically. The authors concluded that these
symptomatic differences were most likely due to developmental alterations caused by in utero SSRI exposure.
Stephannson et al. conducted a retrospective cohort study in
Nordic countries looking at the use of SSR!s in pregnancy and
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the birth outcome.1 Not only did it look at neonatal mortality
and stillbirths, but it also included data for postneonatal
death which was defined as 28 to 364 days after birth. The
study reported that citalopram, fluoxetine and sertraline
were the most commonly used SSRls, respectively. Importantly, the study did not find a difference in infant mortality rates, stillbirths or postneonatal death between mothers
who had taken SSRis during pregnancy compared to those
who did not.

Management of Symptoms
The symptoms of SSRI-induced NAS usually resolve on their
own.11 However in some cases, active management is required. In such cases, treatment of NAS must begin within
two hours of birth, as untreated NAS symptoms can cause
irreversible physical and emotional damage to newborns.1 2
The Finnegan Scoring Tool (Table 1) is a complex test utilized by health care professionals to determine the severity
of withdrawal symptoms in neonates and to ensure that the
best possible care is provided to these infants. Every four
hours, the newborn suffering from NAS must be reassessed
in order to determine the next appropriate steps in care, with
three consecutive scores above eight indicating a need for
pharrnacologic therapy. Morphine (0.05 mg/kg) is utilized as
a mainstay of treatment for withdrawal symptoms if the
infant has three initial Finnegan scores that create a sum
higher than 24. If the newborn suffers from polysubstance
dependency, which indicates potential illicit drug use or
polypharmacy in the mother, phenobarbital is utilized as a
first-line therapy following morphine administration. Phenobarbital is not coadministered with morphine, but, instead,
replaces morphine therapy if the Finnegan scores do not
stabilize within two rounds of treatment.
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Alternating between bottle-feeding and use of a pacifier prevents emesis and occupies the infant, lessening bouts of
harsh crying and calming the child during fits of withdrawal.

Long-Term Effects on Neonates
In addition to developing NAS, in utero exposure to SSRis can
have long-term consequences. Oberlander et al. compared
neonatal exposure in the second or third trimester with either a single agent SSRI or paroxetine and clonazepam with a
nonexposed control group.s In addition, they also grouped
infants based on exposure and symptoms suggesting poor
neonatal adaptation such as jitteriness, respiratory difficulty,
hypoglycemia, lethargy and weak or absent cry. Regardless
of exposure or neonatal symptoms, they did not find a difference in the mental development index (MDI) or psychomotor
development index (PD!) from the Bayley Scales of Infant
Development (BSID) at 2 months and 8 months of age.
Additionally, Nulman et al. prospectively compared child development between three groups of mother-child pairs, one
that took fluoxetine throughout gestation, one that took tricyclic antidepressants, and one that did not have clinical depression and therefore not taking antidepressants.1 4 Children
were evaluated between the ages of 15 and 71 months. There
were no differences found in cognitive and language outcomes, or in temperament between the groups.

The Lipsitz Scoring Tool (Table 1), an alternative test to the
Finnegan Scoring Tool, simplifies the symptom assessment
process and facilitates routine transfers of infants to different levels of care as needed.13 This method requires a nurse
to check the infant and assign a score every three hours
within the first four days after birth. Parameters to be scored
include timing of reflexes, irritability, bowel movements, respiratory distress and presence of vomitus. If a Lipsitz score
of at least four is obtained, the infant must receive care and
more intensive treatment. Table 1 compares the symptoms
assessed in the Finnegan Scoring Tool and the Lipsitz Scoring
Tool.

A second study by Nulman et al. compared intelligence in
four groups of children. 15 Group 1 was born to women that
took venlafaxine, group 2 took SSRis, group 3 was made up of
women who had depression but took no medications and
group 4 consisted of children born to healthy women that
were not depressed. They completed a variety of age appropriate assessments between the ages of 3 and 6 years. In the
groups exposed to antidepressants, 11.3 percent showed
signs of NAS at birth. These children did not show any differences in cognitive function compared to children who did not
show signs of NAS, however some did have differences in
behavioral assessments. Children in groups 1 and 2 did not
show any clinical significant differences compared to group 3
in any of the intelligence quotient (IQ) tests for cognition.
There were differences in IQ and in the behavioral assessments for antidepressant exposed children versus children
who were not exposed. However, the authors concluded that
the cognition difference may have been accounted for by differences in the mother's IQ.

Several nonpharmacologic treatment methods can also help
in the management of NAS symptoms in neonates. These
treatments can be used independently or can help aid pharmacologic treatment. The nonpharmacoiogic treatment includes swaddling, rocking, exposure to calming scents, soft
light and soothing music. These interventions possibly help
by stimulating release of endogenous serotonin levels in infants suffering from NAs.12 Additionally, administering maternal breast milk to the child whenever possible, preferably
milk that does not contain traces of SSRis or other addictive
substances, aids in the recovery of serotonin pathways and
stimulates natural growth and development of the infant.

Since having maternal depression may have adverse neonatal outcomes, Casper et al. compared women who were diagnosed with major depressive disorder (MOD) that remained
medication free versus women diagnosed with MOD that
used SSRis during pregnancy. 1 6Children had follow-up after
six to 40 months. Using BSID II, no significant differences
were found in the MDI between the two groups. They did,
however, find a slight difference on the PD! and the Behavioral Rating Scale (BRS). The group that was exposed to
SSRls in utero had lower scores than those that were not exposed to SSRis. Casper et al. concluded that although there
were differences in the PD! and BRS between the exposed
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Table 1. Finnegan versus Lipsitz Scoring Tools1z,13
Metabolic/ Vasomotor/ Respirato ry Disturbances

Finnegan

Score

Lipsitz

Score

High Pitched Cry
Continuous High-Pitched Crying

2
3

Irritability or
excessive crying

None (0)
Minimal (1)
Moderate (2)
Marked or continuous (3)

Sleeps <l hr after feeding
Sleeps <2 hrs after feeding
Sleeps <3 hrs after feeding

3
2
1

Hyperactive Moro reflex

2

Hyperactive Moro reflex

Normal (0)
Increased (1)
Markedly increased (2)

Mild Tremors
Moderate/severe tremors

1
2

Tremors

None (0)
Minimal (1)
Moderate (2)
Marked increase or continuous (3)

Increased Muscle Tone

2

Muscle Tone

Normal (0)
Increased (1)
Rigidity (2)

Excoriation

1

Skin Abrasions

None (0)
Redness of knees and elbows (1)
Breaking of skin (2)

Myoclonic jerks

3

Generalized convulsions

3

Lipsitz

Score

Central Nervous System Disturbances

Finnegan

Score

Sweating

1

Fever <37.2-38 degrees Celsius
Fever >38.4 degrees Celsius

1
2

Fever

No (0)
Yes (1)

Frequent Yawning

1

Repetitive Yawning

No (0)
Yes (1)

Mottling

1

Nasal stuffiness

1

Sneezing >3-4 times

1

Repetitive Sneezing

No (0)
Yes (1)

Nasal Flaring

2

Respiratory Rate> 60/min
Respiratory Rate >60/min with retractions

1
2

Respiratory Rate

<SS (0)
SS-75 (1)
76-95 (2)

Finnegan

Score

Lipsitz

Score

Excessive Suckling

1

Poor Feeding

2

Regurgitation
Projectile Vomiting

2
3

Vomiting

No (0)
Yes (1)

Loose Stools
Watery Stools

2
3

Stools

Normal (0)
Explosive, normal frequency (1)
Explosive, >8/day (2)

Gastrointestinal Disturbances
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and nonexposed group, these differences may not be clinically significant.
A more recent study conducted by Klinger et al. also evaluated long-term outcomes following SSRI-induced NAS.17 Two
groups of children were assessed, one that had NAS symptoms as evidenced by a Finnegan score of greater than four,
and another group that did not have withdrawal symptoms
(Finnegan score 0-3). Developmental pediatricians evaluated
children at around 3 years of age using the Denver Developmental Screening Test II (DOST-II), which evaluates four areas including gross motor, fine motor-adaptive, language and
personal-social functioning. They did not find a difference in
the overall scores on the DOST-II. However, in the group that
had NAS, children were more likely to have an abnormal
result on the social functioning component. There were no
significant differences found in the intelligence tests. In summary, the combination of studies described above provides
some evidence that SSRls do not have long-term effects on
neurocognitive development but may have long-term behavioral effects.

Role of the Pharmacist: Recognizing at-Risk Pregnant
Women and Combating the Problem
It is important for the pharmacist to recognize NAS associated with SSRI use during pregnancy. The pharmacist may also
play an important role in the inpatient setting by developing
protocols for NAS induced by other drugs such as opiates,
benzodiazepines and other medications. Importantly, pharmacists can contribute significantly in managing depression
during pregnancy.
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tions if it is determined that tapering off SSRls is safe by the
pharmacist and other health care professionals. Two of these
alternative treatments are acupuncture and psychotherapy.
In studies comparing acupuncture and psychotherapy to
SSRls during pregnancy, treatment for both was found to be
comparable to SSRls and well-tolerated, with mild to no side
effects reported.19. 20 It was found that acupuncture yielded
response rates comparable to the rates observed in standard
treatments for depression and was associated with little to
few side effects. However, in the acupuncture study, 90 percent power was not met and included only nine people in the
analysis that did not receive the treatment at alJ.19 In the psychotherapy study, although power was not calculated and
there was a small sample size, recovery criteria was met in
60 percent of women treated and there was a significant
correlation between maternal mood and mother-infant
interaction.20 By recognizing these safer alternatives to
pharmacologic therapy, the pharmacist can recommend
these options to patients and, in consultation with the physician or psychiatrist, undertake a bigger role in managing patients' depression.
If nonpharmacologic treatment is not a viable option, as in
severe cases of depression, SSRis can be used under the direction and supervision of health care providers. However,
SSRI choice and timing are important considerations when
evaluating therapy options. A study by Chambers et al.
looked at birth outcomes in pregnant women taking fluoxetine.21 Specifically, adjusted relative risks were calculated in
those who were exposed to fluoxetine in the third trimester
compared to those who had been exposed to it earlier in the
pregnancy. The study reported that women had a much
greater risk for neonatal problems from later exposure to
antidepressants. The relative risk was 4.8 for prematurity,
2.6 for admission to special care nurseries and 8.7 for NAS. In
summary, the study concluded that women taking fluoxetine
in the third trimester were at increased risk for SSRI-induced
NAS.

Pregnant women struggling with depression can be divided
into two categories; those who may need to be started on
antidepressants while pregnant and those who are already
being treated who will continue their therapy while pregnant.ls In either category, a woman should consult a health
care professional to decide whether to start, change or
continue her therapy regimen while pregnant. This should
include a discussion of both pharmacologic and nonpharmacologic treatments as leaving depression untreated could
have serious health consequences for both the mother and
baby. Counseling pregnant women with depression about
consequences of antidepressant use during pregnancy and
the effects on the developing infant is an important role for
pharmacists in both outpatient and inpatient settings.
Doctors, OBGYNs, psychiatrists, pharmacists and all other
personal health care providers are important in the decisionmaking process.18 Further, pharmacists can look at the diagnosis, confirm the severity of the depression and identify
comorbidities that may complicate treatment. Discussing a
treatment plan with the patient can be complex, as the decision to stop or change medications can come with a risk of
relapse, and generally should not be changed if a patient is
well-controlled on a medication.

As for the other SSR!s, a placental passage study was done at
UCLA Pregnancy and Postpartum Mood Disorders Program
comparing SSRI levels in the mother to the levels in the umbilical cord. 22 The women were receiving one of four SSRls;
citalopram, paroxetine, sertraline or fluoxetine. Each woman
had been taking the medications for at least five half-lives
before delivery. A blood sample was taken from the umbilical
vein before delivery of the placenta. This study found that the
umbilical cord serum concentrations were lower than the
maternal concentrations. The ratio of cord to maternal concentrations of antidepressants ranged from 0.29 to 0.89.
Citalopram produced the highest ratio, followed by fluoxetine, paroxetine and then sertraline. Sertraline had a significantly lower ratio than the rest, which suggests that
sertraline might be the best agent in treating depression in
pregnancy.

Pharmacists can discuss some nonpharmacologic treatment
options that may be useful in patients with mild-moderate
depression to use as substitutes to antidepressant medica-

Many mothers on antidepressant therapy may want to start
breastfeeding, so it is important to also take this into consideration. In a pooled analysis of 67 appropriate studies on
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antidepressant levels in lactating mothers, breast milk and
infants; nortriptyline, paroxetine and sertraline produced
undetectable levels in the infants, making them safest to use
while breastfeeding.23 Fluoxetine produced the highest proportion (22 percent) of infant levels that were elevated
above 10 percent of the average maternal level with citalopram only slightly lower (17 percent). Further research is
needed on this topic. However, it was noted that based on
current evidence, breastfeeding women may reasonably
choose to continue to use antidepressants. Although it appears that sertraline may be the safest option in both populations of women, choosing an antidepressant for pregnant and
breastfeeding mothers is something that should always be
discussed with a doctor and other health care professionals.

11.
12.
13.
14.

15.

16.

17.

Conclusion
With increasing evidence becoming available that SSRI use
during pregnancy may cause NAS, it is becoming more important that health care professionals are aware of the potential short-term and long-term effects of SSRI use during
pregnancy and how they will affect a newborn. Health care
professionals must also be prepared to weigh the risks versus benefits of treating a mother with SSR!s. In addition,
pharmacists play a unique role in recognizing the potential
for NAS and educating other health care professionals to
make them aware of the risk. Then, if needed, the team is
prepared to handle the symptoms. The health care team, particularly pharmacists, can provide both pharmacologic and
nonpharmacologic therapies to expecting mothers needing
antidepressant treatment as well as treat infants that are
experiencing NAS.
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